Pilot Study on Withdrawal of Spironolactone Among Heart Failure With Improved Ejection Fraction
Withdrawal of Spironolactone Treatment for Heart Failure With Improved Left Ventricular Ejection Fractraction: an Open-label Randomized Controlled Pilot Study (With-HF Trial)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Songpa-gu
-
Seoul, Songpa-gu, Korea, Republic of, 138-736
- Asan Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willing and capable of providing informed consent and agrees to follow the study protocol and schedule of clinical follow-up
- Age between 19 and 80 years old
- Prior diagnosis of heart failure with reduced left ventricular ejection fraction (LV EF ≤ 35%) and on medical therapy including spironolactone combined with angiotensin-converting enzyme or angiotensin receptor blocker or antiotensin receptior neprilysin blocker, beta-blocker.
- LV EF ≥ 50% documented with echocardiography performed within a month
- Documented result of BNP or NT-proBNP level within a month
Exclusion Criteria:
- Dyspnea ≥ New York Heart Association (NYHA) functional class III
- Patients who need to discontinue spironolactone owing to prior adverse event
- Primary valvular heart disease with at least moderate degree
- Estimated glomerular filtration rate less than 30 mL/min per 1.73 m2
- Uncontrolled hypertension defined as blood pressure more than 140/90 mmHg
- Presence of other clinical reason to continue spironolactone such as myocardial infarction, primary aldosteronism, and liver cirrhosis
- Hyperkalemia defined as serum potassium level less than 3.5 mmol per liter
- Pregnant and/or lactating women
- Life expectancy less than a year
- Patients who are not suitable to enrollment by investigator's discretion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Withdrawal group
Spironolactone will be discontinued in patients who were receiving optimal medical therapy including angiotensin-converting enzyme or angiotensin receptor blocker or angiotensin receptor neprilysin, beta-blocker, and spironolactone.
|
Other recommended medications for heart failure than spironolactone will be continued for withdrawal group.
|
|
Active Comparator: Continuation group
Spironolactone will be continued during the study period with other medical therapy in combination.
|
Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of left ventricular ejection fraction
Time Frame: 6 month
|
Proportion of patients with change of left ventricular ejection fraction declining more than 10%
|
6 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Numerical change of left ventricular ejection fraction
Time Frame: 6 month
|
Comparison as continuous variable
|
6 month
|
|
Change of serum level on B-type natriuretic peptide or N-terminal pro-brain natriuretic peptide
Time Frame: 6 months
|
Each serum level transformed with a log value and comparing with baseline level
|
6 months
|
|
Change of serum level of biomarkers (e.g. soluble ST-2, galectin-3)
Time Frame: 6 months
|
Serum biomarkers such as soluble ST-2, galectin-3 are checked and compared with baseline value for prediction of decreased left ventricular ejection fraction
|
6 months
|
|
Rates of death, re-hospitalization or visit on emergency department for heart failure
Time Frame: 6 months
|
Adverse clinical events
|
6 months
|
|
results of each outcomes during extended follow-up period
Time Frame: 2 years
|
change of echocardiographic parameters, clinical events, natriuretic peptide
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AMC_2020_0613
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.